1350289-85-8

Guselkumab is a recombinant human IgG1 monoclonal antibody against the IL-23p19 subunit. Guselkumab binds to human and cynomolgus monkey IL-23 with Kd values of 3.3 and 1.9 pmol/L, respectively. Guselkumab inhibits production of cytokines lying downstream of the IL-23 signaling pathway and can be used for psoriatic arthritis research[1].

IL-23: .06 nM (IC₅₀)

[1] International non-proprietary name: guselkumab Procedure No. EMEA/H/C/004271/0000par-public-assessment-report_en.pdf
[2] Li Li, et al. IBI112, a selective anti-IL23p19 monoclonal antibody, displays high efficacy in IL-23-induced psoriasiform dermatitis. Int Immunopharmacol DOI:10.1016/j.intimp.2020.107008